Investment Rating - The investment rating for Cofoe Medical Technology Co., Ltd. is maintained as Outperform [3][8]. Core Insights - Cofoe Medical has signed a strategic cooperation agreement with Royal Philips to enhance the availability of high-quality home health monitoring devices in China [3][8]. - The company achieved revenue of RMB 2.40 billion in the first three quarters of 2025, reflecting a growth of 6.63%, with a net profit attributable to shareholders of RMB 260 million, up by 3.30% [3][8]. - The gross profit margin (GPM) was reported at 53.35%, an increase of 1.97 percentage points, while the net profit margin (NPM) was 10.82%, a decrease of 0.38 percentage points [3][8]. - A target price of RMB 53.84 is set based on a price-to-earnings (PE) ratio of 30X for 2025, considering the company's rapid growth and comparable company valuations [3][8]. - The partnership will allow Cofoe Medical to obtain brand authorization for various Philips home health monitoring devices, including glucometers, blood pressure monitors, and more, facilitating local production and brand operations [3][8]. Financial Summary - For 2023A, total revenue is projected at RMB 2,854 million, with a net profit of RMB 254 million [3][5]. - The company expects to see revenue growth of 12.6% in 2025E, reaching RMB 3,358 million, and a net profit increase of 20.3%, totaling RMB 375 million [3][5]. - The earnings per share (EPS) is forecasted to grow from RMB 1.22 in 2023A to RMB 1.79 in 2025E [3][5]. - The return on equity (ROE) is expected to improve from 5.2% in 2023A to 7.6% in 2025E [3][5].
可孚医疗（301087）：可孚医疗引入飞利浦家庭健康监测设备